Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections

[1] Blimark C(2015)Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients Haematologica 100 107-113

[2] Holmberg E(2018)Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study Haematologica 103 e300-e303

[3] Mellqvist UH(2019)The expanding field of secondary antibody deficiency: causes, diagnosis, and management Front Immunol 10 33-62

[4] Landgren O(2019)Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) Leukemia 33 844-591

[5] Bjorkholm M(2014)Secondary antibody deficiency Expert Rev Clin Immunol 10 583-70

[6] Hultcrantz M(2018)A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia Expert Rev Hematol 11 57-7

[7] Andersen MA(2016)Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients Blood Cancer J 6 e499-63

[8] Eriksen CT(1988)Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial N Engl J Med 319 902-772

[9] Brieghel C(1994)Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma Lancet 343 1059-14

[10] Biccler JL(2009)Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis Leuk Lymphoma 50 764-33

[1] Blimark C(2015)Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients Haematologica 100 107-113

[2] Holmberg E(2018)Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study Haematologica 103 e300-e303

[3] Mellqvist UH(2019)The expanding field of secondary antibody deficiency: causes, diagnosis, and management Front Immunol 10 33-62

[4] Landgren O(2019)Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) Leukemia 33 844-591

[5] Bjorkholm M(2014)Secondary antibody deficiency Expert Rev Clin Immunol 10 583-70

[6] Hultcrantz M(2018)A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia Expert Rev Hematol 11 57-7

[7] Andersen MA(2016)Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients Blood Cancer J 6 e499-63

[8] Eriksen CT(1988)Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial N Engl J Med 319 902-772

[9] Brieghel C(1994)Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma Lancet 343 1059-14

[10] Biccler JL(2009)Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis Leuk Lymphoma 50 764-33